This population-based descriptive cohort study examined the association between a first-time hospital discharge diagnosis of recurrent cystitis and subsequent diagnoses of urologic cancer in Denmark between 2006 and 2022. Patients with prior cancer were excluded. Cancer outcomes were ascertained through the Danish Cancer Registry. The authors report both absolute risks (cumulative incidences) and relative risks expressed as standardized incidence ratios (SIRs) compared with the general population.
Cases of recurrent cystitis were identified via the Danish National Patient Registry. Urologic cancer diagnoses—encompassing cancers of the urinary bladder, kidney, ureter, renal pelvis and prostate—were ascertained using the Danish Cancer Registry. The analysis calculated cumulative incidences and SIRs using incidence rates from the general population. The source text does not provide further procedural details in the excerpt provided here.
The cohort comprised 42,377 adults with hospital-diagnosed recurrent cystitis. Women constituted 68% of the cohort, and the median age was 62 years. Median follow-up time was 5.7 years. During follow-up, 1,047 patients were diagnosed with a urologic cancer.
Within the first year after the hospital discharge diagnosis of recurrent cystitis, the 1-year absolute risk (cumulative incidence) of any urologic cancer was reported as 1.2% (95% confidence interval [CI], 1.1–1.3%). The corresponding 1-year standardized incidence ratio (SIR) was 4.99 (95% CI, 4.56–5.44), indicating a substantially higher incidence of urologic cancer in the first year compared with the general population.
Beyond two years of follow-up, the overall SIR for urologic cancer declined. However, when stratified by sex, the SIR remained elevated only among women, with a long-term SIR of 1.47 (95% CI, 1.20–1.78). The provided source excerpt does not include detailed SIR values for specific urologic cancer subtypes or for men beyond two years.
The authors interpret the markedly increased short-term incidence of urologic cancer following a hospital diagnosis of recurrent cystitis as evidence that recurrent cystitis may act as a clinical marker for underlying urologic malignancy. They note, however, that absolute risks remain low. Consequently, despite the strong relative increase in the short term, the findings do not support routine additional diagnostic cancer work-up for all patients with recurrent cystitis based on the data presented in the excerpt.
The study is set against a background of conflicting evidence on UTI-related cancer risk. Prior observational studies and two meta-analyses—mainly of case-control designs—have suggested an association between recurrent UTI and bladder cancer but with substantial between-study heterogeneity and inconsistent confounder control. Some cohort and population studies have reported elevated risks for specific urologic cancers, and recent nationwide investigations have demonstrated dose-response relationships for rare bladder cancer subtypes and a pronounced short-term increase in urologic cancer after acute cystitis.
Biologically, recurrent infections could promote carcinogenesis through chronic inflammation and related pathways (for example, NF-κB–mediated mechanisms), but the relationship is complex and may be confounded by shared risk factors such as smoking and obesity, which are linked to both infection risk and urologic cancers.
The key clinical implication reported by the authors is that hospital-diagnosed recurrent cystitis should be recognized as a potential clinical marker of underlying urologic cancer because of the striking short-term relative increase in diagnoses. Nonetheless, because the absolute short-term risk is relatively low (1.2% at one year), the study does not recommend additional routine cancer diagnostic work-up for all patients with recurrent cystitis based on the data excerpted here.
The provided source text highlights that the pronounced short-term rise in cancer diagnoses could reflect alternative explanations such as detection bias or misinterpretation of symptoms, given symptom overlap between infection and urologic cancer. The excerpt does not supply further methodological limitations, subgroup analyses, or sensitivity analyses; those details were not reported in the text provided.
In this nationwide Danish cohort of adults with first-time hospital-diagnosed recurrent cystitis (2006–2022), there was a large relative increase in urologic cancer diagnoses during the first year after diagnosis and a persistently elevated long-term risk observed among women only. The authors suggest that recurrent cystitis can be a clinical marker of urologic cancer but, given low absolute risks, do not advocate routine additional diagnostic cancer work-up for these patients based on the data presented in the source excerpt.